Lipitor's specter casts earnings shadow, diabetes boosts Novo

Share this article:
Delaying its earnings report by three days put Pfizer's numbers in Halloween's shadow. Revenues were down 16% for the quarter, at $14 billion compared to sales of $17 billion for the same period last year.

Lipitor continued to haunt the company, with a relatively scant $749 million in sales for the quarter -- a 71% drop worldwide compared to $2.6 billion in sales for the same period last year. The statin went generic in November 2011. The company said statin losses lowered primary care revenues by about $2.4 billion for the quarter compared to last year, but global sales of Lyrica and Celebrex helped dampen the impact. The company also had major falloff in sales of its anti-psychotic Geodon, at $57 million in quarterly sales -- a 78% drop from $263 million for the same period last year -- and a 55% falloff in sales of Caduet, with $68 million for the quarter compared to $150 million for the same period last year.

At the same time, the specter of past layoffs materialized in lower Selling, Informational and Administrative expenses, which were down 14% for the quarter. The company said the core of these savings came from “reduction in the field force and a decrease in promotional spending.”

Pfizer also took a look at upcoming events, noting that its RA drug tofacitinib comes up for FDA review this month and that blood-thinner Eliquis is up for review in March. The company said the IPO for Zoetis, its animal health spin-off, looks set for the first half of next year.

Novo Nordisk said it wrapped up the third quarter with $3.4 billion in sales, a 20% increase from the same period last year. The bulk of the growth came from its diabetes business, specifically Victoza and three other insulins, with the US and Europe providing the majority of Victoza's steam. The company was also 1,485 employees heavier, compared to the same period last year, and attributed the increase to expansion in the US and international operations.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...